Introduction {#S5}
============

Fetal metabolism is dependent upon substrates from the maternal nutrient environment. While evidence suggests that fatty acid synthesis is active before term ^[@R1],\ [@R2]^, little is known about fetal fatty acid desaturase pathways, which are subject to hormonal and nutrient regulation. Mouse fetal lung tissues have demonstrated Δ9 stearoyl-CoA desaturase expression ^[@R3]^, while human fetal liver samples have been shown to exhibit Δ5 and Δ6 desaturase activities ^[@R4]^. Whether maternal conditions during pregnancy affect (i.e. "program") fetal desaturase activity is not known.

Stearoyl CoA desaturase enzyme-1 (SCD1) is a lipogenic Δ9 desaturase ^[@R5]^ that is upregulated in obesity and insulin resistance ^[@R6],\ [@R7]^. SCD1 converts saturated fatty acids (SFA) (16-carbon palmitic acid, 16:0, and 18-carbon stearic acid, 18:0) to monounsaturated fatty acids (MUFA) (palmitoleic 16:1n-7, and oleic 18:1n-9, respectively) for incorporation into triglycerides. Using gas chromatography/mass spectrometry (GC/MS), the fatty acid composition of tissues can be determined. Through GC/MS, SCD1 activity can be estimated from the desaturation indices, the product-to-precursor ratios (palmitoleic/palmitic 16:1n-7/16:0, and oleic/stearic 18:1n-9/18:0) ^[@R8],\ [@R9]^. In obesity, the desaturation indices correlate with measures of adiposity in animal tissues ^[@R10]^, and in human subjects ^[@R11],\ [@R12]^. SCD1 expression is responsive to the nutrient and hormonal environments, with induction by carbohydrates ^[@R13]^ and fat ^[@R14]^, but with suppression by polyunsaturated fatty acids (PUFA) ^[@R15]^. SCD1 is induced by insulin, but suppressed by leptin ^[@R16]^.

Gestational diabetes (GDM) exposes the fetus to changes in the in utero nutrient environment. While adult human studies have shown that plasma reflects hepatic SCD1 expression ^[@R9]^, this has not been confirmed in fetal life, and we explore this concept in the present study. Preterm infants have demonstrated de novo synthesis of monounsaturated fatty acids, supporting the likelihood that hepatic SCD1 is active in utero ^[@R17]^. Therefore, we hypothesized that unfavorable maternal conditions in GDM may stimulate fetal SCD1 activity, resulting in increased cord plasma desaturation. The objectives of this study were 1) to compare the cord plasma desaturation indices in GDM and Control newborns, and 2) to determine whether the indices were related to infant anthropometric or biochemical measures. We demonstrated a higher oleic/stearic desaturation index in cord plasma of GDM newborns, which may be related to measures of infant adiposity.

Materials and Methods {#S6}
=====================

Study subjects and cord blood sample collection {#S7}
-----------------------------------------------

The study was approved by the Human Subjects Committee at the Los Angeles Biomedical Research Institute at Harbor-UCLA (the study center, Torrance, CA). When expectant mothers were admitted for labor, informed consent was obtained from those who were interested in enrolling their infants in a prospective study intended to follow up to three years of age. Infants born to mothers with GDM (GDM), and normal weight infants of mothers without diabetes (Control) were recruited at 37-42 weeks gestational age. (Small-for-gestational age infants were also recruited, but there were insufficient numbers for analysis.) GDM in the mother was determined using previously established diagnostic criteria ^[@R18]^, and managed by their personal physicians. Control infants had estimated weight \>10^th^ percentile and \<90^th^ percentile for age and gender ^[@R19]^, confirmed after delivery.

Infants were excluded for multiple gestation, unknown dates, pre-pregnancy maternal diabetes, and syndromic/chromosomal conditions. GDM subjects born SGA were excluded from this analysis.

Umbilical venous cord blood was collected by needle and syringe from the clamped cord after delivery, except in five samples, for which the mode of collection was not documented. The study subjects were evaluated by physical examination, anthropometric measurements, chart review, and maternal interview including a 24-hour dietary recall. Newborn findings are presented in this report.

Anthropometrics {#S8}
---------------

Birth weights were recorded by hospital personnel immediately after delivery. Recumbent infant lengths were determined using a Kiddimeter (Raven Equipment Limited, Essex, UK) in all but a few subjects, for whom tape measure lengths were used. Head circumference was measured at the widest occipitofrontal circumference. The ponderal index was calculated ^[@R20]^. Weight-for-length percentiles were based on CDC growth charts from the year 2000. Percent body fat was determined by the summation of skinfold thickness measurements (triceps, biceps, suprailiac, and subscapular) obtained by Holtain calipers generally at 12-48 hours of life, using the following equations for total body density: Male: d=1.1690-0.0788Log(sum of skinfolds), Female: d=1.2063-0.0999Log(sum of skinfolds) ^[@R21]^. Waist circumference was determined at the level just above the umbilicus.

Biochemical measures of metabolism {#S9}
----------------------------------

Serum (for total cholesterol, LDL, HDL, and triglycerides) and plasma (for all other measures) were isolated from cord blood by centrifugation as soon as possible after collection. Samples were stored at -80°C until analysis. The following biochemical measures were obtained: plasma glucose levels (hexokinase method, Sigma); adiponectin (Linco Human Adiponectin ELISA kit, Millipore); leptin (Linco Human Leptin ELISA kit, Millipore); C-peptide ( Human C-peptide Radioimmunoassay, Millipore); insulin (fluoroimmunoassay, Beckman Coulter); Non-esterified fatty acid (NEFA) levels (enzymatic colorimetric method assay, Wako); total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels (Beckman Coulter Unicel® DxC 800 system, timed endpoint methods).

Plasma fatty acid analysis {#S10}
--------------------------

### Fatty acid extraction and GC/MS {#S11}

Total fatty acids (including those from triglycerides, phospholipids, and cholesteryl esters) were extracted from 50 μl plasma. Plasma underwent saponification, acidification, and petroleum ether extraction as previously described ^[@R22]^. Fatty acids were derivatized as methyl esters for GC/MS analysis using a Hewlett-Packard model 6890 gas chromatograph, with a Bpx70 column (30-m length, 250-μm diameter, 0.25-μm film thickness; SGE, Inc., Austin, TX), and a model 5973 selective mass detector (not flame ionization detector, FID). Gas chromatography conditions were: helium flow rate, 1 ml/min; initial oven temperature, 150°C, programmed to increase at 3°C/min to a final temperature of 221°C. Expected retention times for palmitic, palmitoleic, stearic, and oleic acids based on known standards were: 6.6, 7.2, 9.5, and 10.2 minutes, respectively. Mass spectra of fatty acids were obtained through electron impact ionization, with the mass detector set in scan mode, and a 2 minute solvent delay. The identities of the following fatty acids were confirmed by observation of their characteristic ions between m/z 200-400: palmitic, m/z 270; palmitoleic, m/z 268 and 236; stearic, m/z 298; oleic, m/z 296, 264. Fatty acids were considered undetectable if a peak was too low for integration, or the mass spectrum of a peak at the expected retention time did not show characteristic ions. Samples were run in triplicate and the relative abundance is presented as a percent of total fatty acids.

The GC/MS methods were validated by standard curves, demonstrating variation in ionization efficiencies among the fatty acids when each one was analyzed against an internal standard. Measured-to-actual response factors include: palmitic 0.93, palmitoleic 0.33, stearic 1.50, oleic 1.57, arachidonic (ARA) 0.35, and docosahexaenoic acid (DHA) 0.25. (Therefore, in comparison to other studies ^[@R23],\ [@R24]^, the palmitic acid and DHA abundances with our methods seem lower, while stearic acid seems higher.)

### Calculation of desaturation indices {#S12}

The area under each GC peak is proportional to the relative abundance of each fatty acid. Desaturation indices were determined by calculating the ratios of relative abundances of the MUFA products (palmitoleic, oleic) to saturated fatty acid (SFA) precursors (palmitic, stearic). The palmitoleic/palmitic and oleic/stearic desaturation indices ^[@R8],\ [@R11],\ [@R12]^ were calculated.

### VLDL isolation {#S13}

Cord plasma VLDL desaturation indices were determined as a surrogate measure of fetal liver SCD1 activity ^[@R9]^ from 10 Control and 10 GDM subjects. (Insufficient samples to analyze in the whole cohort.) Preliminary chylomicron separation was not done due to their absence in cord plasma ^[@R25]^. A previously published method for VLDL isolation ^[@R26]^ was adapted for smaller volumes. Briefly, 250 μl of plasma was overlaid with 150 μl 1.006 g/mL density NaCl/KBr solution in Ultra Clear thin-walled tubes, then ultracentrifuged with tube adaptors (SWTi55 rotor, Beckman Coulter) for 20 hours at 45,000 rpm at 4°C. VLDL was removed in the top 120 μl of supernatant. Fatty acids were extracted and analyzed as above with tri-deuterated heptadecanoic acid as an internal standard.

Maternal dietary intake -- 24 hour recall {#S14}
-----------------------------------------

Maternal dietary intake was estimated by recall of the 24 hour period before food was withheld before delivery. The Nutrition Data System for Research Software generated intake values based on the University of Minnesota Nutrition Coordinating Center Food and Nutrient Database. Mothers were asked whether the recall represented "typical" (average), more, or less than usual intake.

Statistical Methods {#S15}
-------------------

Based on data available at the time of the study design ^[@R8]^, 20 subjects per group was estimated to provide 80% power to detect a 36% difference in the 16:1/16:0 ratio and a 20% difference in the 18:1/18:0 ratio between groups with p\<0.05. The primary outcomes were the palmitoleic/palmitic and oleic/stearic indices. Secondary outcomes included infant and maternal data, anthropometrics, cord plasma biochemical measures, and maternal dietary data. Statistical analysis was performed using SYSTAT (v13) and SigmaPlot 11.0. Values below limits of detection were assigned numerical values that were half of the lowest detectable limit of each assay. Normally distributed data was analyzed by ANOVA. Non-parametric data (e.g. glucose, insulin, leptin, triglycerides, dietary data) was analyzed by the Kruskal-Wallis ANOVA on Ranks. The significance level was set at 0.05. The data sets that include nonparametric data are presented as medians with 25-75% IQR for consistency in presentation. Gender distribution was compared using Fisher\'s exact test.

The primary ANOVA was extended to multiple regression analysis that adjusted for baseline variation (gestational age and gender), and potential confounding characteristics that were significantly different between groups (maternal age, log-transformed glucose). Insulin was not included due to non-normal distribution despite log-transformation.

Each desaturation index was correlated to maternal and infant factors related to adiposity and insulin resistance in the whole cohort, and in each group separately, using Pearson\'s correlations for normally distributed data, and Spearman\'s correlations for non-parametric data. The correlations were determined to determine if GDM status affected the relationships. Linear regression was performed to assess effect of maternal diabetes treatment within GDM. No mathematical correction was made for these secondary exploratory analyses, but note that they comprise over 50 correlations.

Results {#S16}
=======

Infant Characteristics {#S17}
----------------------

The ethnic group composition was representative of the patient population at the study center. In the Control group, 20 subjects were Hispanic, 1 was Black, and 1 was mixed Hispanic/White. In the GDM group, 19 were Hispanic, 1 was Asian, and 1 was mixed Hispanic/White.

Of the GDM mothers, 9 were treated by diet and lifestyle modification, 9 received metformin treatment, 2 were treated by glyburide alone, and 1 mother received insulin.

Of the subject characteristics ([Table 1](#T1){ref-type="table"}), the GDM group demonstrated higher maternal age (p=0.002). GDM mothers trended toward less weight gain during pregnancy (p=0.07). The remaining maternal characteristics were similar between groups. Mean maternal HbA1c (available from 18 GDM mothers, majority drawn during third trimester) was 5.6% ([Table 1](#T1){ref-type="table"}), indicating adequate glycemic control ^[@R27]^. Infant birth weight and percent body fat were similar between Controls and GDM.

Biochemical measures of metabolism, fatty acid profile, and desaturation indices {#S18}
--------------------------------------------------------------------------------

In the cord plasma biochemical measures ([Table 2A](#T2){ref-type="table"}), GDM plasma exhibited significantly higher glucose (p=0.006) and insulin measurements (p=0.04). For the lipid panels, 3 samples were insufficient for analysis in each of the Control and GDM groups, but results were similar between groups. There was a trend toward higher leptin concentrations (p=0.07) in GDM.

Of the percentages of total of the fatty acids of interest ([Table 2B](#T2){ref-type="table"}), GDM infants show lower abundance of palmitic (p=0.01), and stearic acid (p\<0.001), while the abundances of myristic (a minor product of de novo synthesis), vaccenic (elongation product of palmitoleic acid) were similar. Of the PUFAs, the percentages of linoleic, ARA, and DHA were similar. Less than half of the subjects had detectable α-linolenic acid (ALA) or eicosapentaenoic acid (EPA), and the percent of total for each averaged less than 1% (not shown).

The total plasma palmitoleic/palmitic acid index was similar between the two groups ([Table 2B](#T2){ref-type="table"}). The GDM infants demonstrated significantly higher oleic/stearic acid indices than Controls (p\<0.001).

VLDL desaturation indices {#S19}
-------------------------

Palmitoleic acid was not detected in two Controls. Among the SFA and MUFA, there were similar percentages of total of palmitic (expressed as median and IQR) (Control 17.8, IQR 15.7-20.4%; GDM 19.6, IQR 16.6-23.7%), and stearic (Control 43.4, IQR 27.9-54.4%; GDM 29.6, IQR 21.4-48.2%) acids. GDM trended toward higher palmitoleic abundance (Control 0.4, IQR 0.2-0.7%; GDM 1.4, IQR 0.4-2.8%), but had significantly higher oleic (Control 7.0, IQR 3.5-21.0%; GDM 19.3, 17.3-25.1%) and vaccenic acid proportions (Control 0.2, IQR 0.0-0.3%; GDM 1.5, IQR 1.0-2.1%). GDM demonstrated higher VLDL oleic/stearic indices than Controls (p=0.03) ([Table 2B](#T2){ref-type="table"}).

Multiple regression {#S20}
-------------------

The total plasma desaturation indices between Control and GDM groups were compared in multiple regression analyses, with adjustment for potential confounding factors. After adjustment for gestational age and gender, the palmitoleic/palmitic ratio was still similar between groups, with the least square means (LSM) ± SEM 0.11±0.01 in Controls, versus 0.12±0.01 in GDM, p=0.25. The oleic/stearic ratio remained significantly higher in the GDM group (Control 0.72±0.09; GDM 1.24±0.09, p\<0.001). After further adjustment for factors that were increased in the GDM group - maternal age and glucose concentrations (log-transformed for regression) - the palmitoleic/palmitic ratio remained similar between groups (Control 0.10±0.01; GDM 0.12±0.01, p=0.09), and the oleic/stearic ratio remained higher in the GDM group (Control 0.67±0.11; GDM 1.29±0.11, p=0.001).

Maternal dietary intake -- 24 hour recall {#S21}
-----------------------------------------

There were no differences in dietary intake measures between the groups ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}). Subjectively, mothers often had trouble recalling their food intake prior to delivery (dietary interviews were conducted postpartum). One mother in the Control group and 2 mothers in the GDM group could not tell study personnel whether their reported intake represented more, less, or "typical" intake (average amount). Of the mothers who did answer, intake was reported to be typical by 36% of Control mothers, and 57% of GDM mothers, while the remaining mothers reported less intake.

Correlations {#S22}
------------

With regards to measures of adiposity, the palmitoleic/palmitic index correlated positively with birth weight (p=0.03; [Figure 1A](#F1){ref-type="fig"}), while the oleic/stearic index trended to a positive correlation (p=0.06, [Figure 1B](#F1){ref-type="fig"}). Neither desaturation index correlated significantly with percent body fat (palmitoleic/palmitic, r=0.23; oleic/stearic, r=0.24), or the weight-for-length percentile (palmitoleic/palmitic r=0.03; oleic/stearic r=-0.05). Of note, both indices positively correlated with waist circumference (palmitoleic/palmitic p=0.001, [Figure 1C](#F1){ref-type="fig"}; oleic/stearic p=0.01, [Figure 1D](#F1){ref-type="fig"}), with GDM contributing more to the associations than Controls.

With respect to glucose metabolism, the palmitoleic/palmitic index ([Figure 1E](#F1){ref-type="fig"}) was unrelated to glucose, while the oleic/stearic index correlated positively ([Figure 1F](#F1){ref-type="fig"}). Neither index correlated with insulin (palmitoleic/palmitic, r~s~=0.22; oleic/stearic, r=0.24) or C-peptide (palmitoleic/palmitic, r=0.05; oleic/stearic, r=0.11). While neither index correlated with leptin in the total cohort of Control and GDM subjects (palmitoleic/palmitic, r~s~=0.0013, [Figure 1G](#F1){ref-type="fig"}; oleic/stearic, r~s~=0.19), the two groups exhibited different patterns in the palmitoleic/palmitic index, with the Controls demonstrating a trend to negative association with leptin (Control r~s~= -0.40, p=0.06; GDM r~s~=0.18). Neither index correlated significantly with adiponectin (palmitoleic/palmitic, r=0.24; oleic/stearic, r=0.13). Neither desaturation index correlated overall with maternal prepregnancy BMI (palmitoleic/palmitic, r~s~=-0.22, [Figure 1H](#F1){ref-type="fig"}; oleic/stearic, r~s~=0.01). However the Control group palmitoleic/palmitic index was negatively associated (Control r~s~= -0.57, p=0.006; GDM r~s~=-0.1). Within the GDM group, neither desaturation index correlated significantly with type of maternal diabetes treatment (palmitoleic/palmitic, R^2^=0.18, oleic/stearic R^2^=0.28). Neither desaturation index correlated with maternal intake of palmitic, palmitoleic, stearic, or oleic acids (not shown).

Discussion {#S23}
==========

While increased SCD1 desaturation has been demonstrated in obesity in multiple populations ^[@R12],\ [@R28],\ [@R29]^, we sought to determine whether increased desaturation was present in newborns of mothers with gestational diabetes as well. Despite average birth weights and percent body fat, GDM infants demonstrated higher cord plasma oleic/stearic desaturation indices, which may be partially influenced by maternal supply of glucose. Both desaturation indices may be related to certain measures of adiposity. Our data also suggests that fetal liver SCD1 activity contributes to the higher cord plasma oleic/stearic desaturation index in GDM infants.

The GDM group demonstrated a greater total plasma oleic/stearic desaturation index, with lower stearic acid abundance that may represent increased turnover of stearic in conversion to oleic acid. A similar decrease in palmitic acid abundance in GDM did not lead to a difference in the palmitoleic/palmitic desaturation index, suggesting that the 16-carbon and 18-carbon fatty acid desaturation pathways may be functionally compartmentalized or differentially regulated ^[@R30]^. Other potential explanations include influence from maternal blood, or dilution from fatty acids released by lipolysis. However, our data is limited by lack of maternal fatty acid profiles for comparison.

Regarding maternal characteristics, the mothers varied in treatment of diabetes, and were predominantly Hispanic. Metformin (but not glyburide) crosses the placenta ^[@R31]^, and data published after the inception of this study suggests that metformin may suppress hepatic SCD1 ^[@R32]^. However, there was no correlation between either desaturation index and type of diabetes treatment. The predominance of Hispanic subjects in this study enhanced comparability between groups, but limits generalizability to other populations. Therefore, further studies are needed to determine whether maternal diabetes treatment or ethnicity influence SCD1 desaturation in cord plasma.

Both glucose and insulin are known to stimulate SCD1 activity ^[@R33]^. Cord glucose may be influenced by maternal supply, while insulin concentrations reflect the fetal response ^[@R34]^. The correlation between glucose concentrations and the oleic/stearic indices in our study suggests a fetal elevation of SCD1 activity in response to maternal glucose supply in GDM. However, adjustment for glucose measurements in the multiple regression analysis did not diminish the elevation in the oleic/stearic index in the GDM group. Along with the acceptable HbA1c values, these findings would suggest that factors in addition to glucose influence the fetal desaturation indices in GDM pregnancies, and the indices are unlikely to be modified by even tighter glucose control.

The higher VLDL oleic/stearic desaturation index in GDM suggests that the fetal liver contributes to the difference in the total plasma oleic/stearic index. Cord plasma fatty acids are derived from maternal ^[@R35]^, placental ^[@R36]^, and fetal sources ^[@R1]^. However, maternal lipoproteins do not cross the placenta intact, and therefore we analyzed cord VLDL as a fetal-specific lipoprotein. As the main lipid export product of the liver, VLDL includes products of liver fatty acid metabolism. VLDL desaturation indices have been shown to correlate with liver SCD1 mRNA expression in humans ^[@R9]^, and are therefore, markers of liver SCD1 expression. Low sample numbers and volumes in the VLDL analysis limited our ability to detect the less abundant palmitoleic acid, but the difference in the oleic/stearic desaturation index remains. Future studies are needed to define how the maternal, placental, and fetal contributions affect the cord plasma desaturation indices.

Although SCD1 activity can be induced by high fat intake ^[@R14]^, our study did not demonstrate evidence of increased maternal fat intake among our GDM mothers. Conversely, there were no differences with PUFA intake that may suppress desaturation. Despite similar concentrations of TGs and NEFAs (which include maternal fatty acids from placental transport), we cannot exclude qualitative differences in NEFA or TG composition that may have affected fetal desaturase activity.

Low concentrations of adiponectin are associated with insulin resistance in obesity and diabetes ^[@R37],\ [@R38]^. We found no relationship between adiponectin and the desaturation indices, in contrast to published studies finding that the oleic/stearic desaturation index was inversely correlated with adiponectin in plasma of healthy adolescent females ^[@R39]^, and in the adipose tissue of adults with rare adipose disorders ^[@R40]^. More studies are needed to determine what factors determine this relationship (or lack thereof). The similar leptin levels between Controls and GDM are consistent with data showing that leptin correlates with birth weight ^[@R20]^. With respect to desaturase activity, leptin regulates liver SCD1 expression through suppression ^[@R16]^. However, the palmitoleic/palmitic index in only the Control group trended toward a negative association with leptin concentrations. Whether lack of a similar trend in GDM suggests an abnormal relationship with leptin requires further investigation.

While the unexpected strong negative association between the palmitoleic/palmitic index and maternal pre-pregnancy BMI among Control, but not GDM subjects, suggests a relationship that may be dysregulated in GDM, the data overall supports that cord desaturation is associated with factors other than maternal obesity. Among the infants, however, the correlation between both total desaturation indices and the waist circumference among Controls and GDM was of particular interest. Associations between desaturation indices and adiposity were previously documented in adolescence ^[@R12]^ and adulthood ^[@R11]^. Because the abdominal circumference reflects fetal growth in utero ^[@R41]^, and the waist circumference may be a measure of adiposity in very young children ^[@R42],\ [@R43],\ [@R44]^ and adolescents ^[@R45]^, we infer that the waist circumference may represent adiposity in the newborn as well. Future investigations are needed to determine whether the correlation between the indices and waist circumference can be used to predict future obesity and insulin resistance.

Conclusions {#S24}
===========

The findings from this study support a complex relationship between maternal, placental, and fetal factors and the total cord plasma desaturation indices. Overall, elevations in the oleic/stearic desaturation indices are present in GDM, despite normal birth weight and good maternal diabetes control during pregnancy. Although the oleic/stearic index appears to be influenced by glucose supply from the mother, additional factors are likely involved in stimulation of SCD1 activity in GDM. Both desaturation indices appear related to infant waist circumference. The difference in the total plasma oleic/stearic index may be influenced by liver desaturase activity. Whether the increased oleic/stearic desaturation index in GDM persists through early childhood will be determined in our long-term follow-up study. How the cord plasma desaturation indices may be used as biomarkers of clinical outcome in the development of obesity and metabolic disease requires further investigation.
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![Correlations between total desaturation indices and measures of adiposity or glucose metabolism\
r indicates Pearson\'s correlation coefficient, while r~s~ indicates Spearman\'s correlation coefficient. \*p\<0.05, \*\*p\<0.01. The palmitoleic/palmitic index correlated with birth weight (A), but the oleic/stearic index did not (B). Both the palmitoleic/palmitic and oleic/stearic indices were positively associated with waist circumference (C and D). In relation to glucose concentrations, the palmitoleic/palmitic index was not related to glucose (E), but the oleic/stearic index positively correlated (F). Among Controls only, the palmitoleic/palmitic index trended toward a negative correlation with leptin (G), and a significant negative correlation with maternal prepregnancy BMI (H).](nihms553847f1){#F1}

###### Characteristics of infants[1](#TFN1){ref-type="table-fn"}

  Characteristics                                   Control(n=22)   GDM(n=21)
  ------------------------------------------------- --------------- ------------------------------------------
   Gender, *male/female*                            10M/12F         12M/9F
   Gestational Age, *weeks*                         39.6 ± 0.2      39.7 ± 0.2
  Maternal Characteristics                                          
   Maternal Age, *years*                            27 ± 1          33 ± 1[\*\*](#TFN2){ref-type="table-fn"}
   Parity, including subject                        2.4 ± 0.4       2.1 ± 0.2
   Maternal Prepregnancy BMI, *kg/m^2^*             27.3 ± 2.0      31.0 ± 1.5
   Maternal Pregnancy Weight Gain, *kg*             12.6 ± 0.8      8.8 ± 1.6
   Maternal Delivery BMI, *kg/m^2^*                 32.1 ± 1.9      34.7 ± 1.4
   Maternal HbA1c, *%*                              N/A             5.6 ± 0.1 (n=18)
  Infant Anthropometrics                                            
   Infant Birth Weight, *kg*                        3.43 ± 0.07     3.53 ± 0.8
   Infant Birth Length, *cm*                        49.8 ± 0.4      50.7 ± 0.3
   Head Circumference, *cm*                         34.3 ± 0.2      31.3 ± 1.8
   Ponderal Index, *kg/m^3^*                        2.79 ± 0.05     2.72 ± 0.07
   Weight-to-length Percentile, *%*                 59.0 ± 5.1      48.4 ± 6.3
   Infant Percent Body Fat, *%*(sum of skinfolds)   10.8 ± 0.6      12.2 ± 0.8
   Infant Waist Circumference, *cm*                 32.3 ± 0.4      33.0 ± 0.5

Data are presented as the mean ± SEM.

p\<0.01 compared with Controls

###### Biochemical measures, profile of fatty acids of interest, and desaturation indices[1](#TFN3){ref-type="table-fn"}

  A.                                                                                 Control (n=22)     GDM (n=21)
  ---------------------------------------------------------------------------------- ------------------ ----------------------------------------------------
  Cord Plasma Biochemical Measures                                                                      
  Glucose,*mmol/L*                                                                   3.8 (3.0-4.2)      4.7 (4.5-5.6)[\*\*](#TFN8){ref-type="table-fn"}
  Insulin, *pmol/L*                                                                  27.8 (16.7-50.0)   45.8 (26.3-69.5)[\*](#TFN7){ref-type="table-fn"}
  C-peptide, *nmol/L*                                                                0.13 (0.08-0.17)   0.10 (0.07-0.15)
  Total Cholesterol, *mmol/L*[2](#TFN4){ref-type="table-fn"}                         1.58 (1.35-1.89)   1.49 (1.14-1.66)
  LDL cholesterol, *mmol/L*[2](#TFN4){ref-type="table-fn"}                           0.80 (0.67-0.90)   0.71 (0.57-0.85)
  HDL cholesterol, *mmol/L*[2](#TFN4){ref-type="table-fn"}                           0.67 (0.52-0.92)   0.54 (0.44-0.78)
  Triglycerides, *mmol/L*[2](#TFN4){ref-type="table-fn"}                             0.19 (0.15-0.32)   0.20 (0.12-0.28)
  NEFA, *mmol/L*                                                                     0.12 (0.09-0.17)   0.12 (0.11-0.18)
  Leptin, *μg/L*                                                                     8.8 (6.2-10.4)     10.9 (7.6-15.6)[\#](#TFN9){ref-type="table-fn"}
  Adiponectin, *mg/L*                                                                36.0 (29.7-49.0)   37.6 (32.6-51.0)
  **B**.                                                                                                
  Total Plasma Abundance of Fatty Acids of Interest[3](#TFN5){ref-type="table-fn"}                      
   14:0 myristic, *% of total*                                                       0.35 (0.28-0.39)   0.46 (0.31-0.72)
   16:0 palmitic, *% of total*                                                       22.1 (20.3-23.3)   19.7 (14.5-21.7)[\*\*](#TFN8){ref-type="table-fn"}
   16:1n-7 palmitoleic, *% of total*                                                 2.3 (1.9-2.8)      2.3 (1.6-2.9)
   18:0 stearic, *% of total*                                                        22.6 (18.1-25.8)   12.9 (10.5-15.2)[\*\*](#TFN8){ref-type="table-fn"}
   18:1n-9 oleic, *% of total*                                                       15.5 (10.9-16.8)   14.4 (12.1-17.6)
   18:1n-7 vaccenic, *% of total*                                                    2.5 (2.0-2.9)      2.6 (2.3-2.8)
   18:2 linoleic, *% of total*                                                       7.8 (6.6-9.5)      6.6 (5.3-10.0)
   20:4n-6 arachidonic (ARA), *% of total*                                           7.9 (6.9-10.1)     8.2 (6.0-13.2)
   22:6n-3 docosahexaenoic (DHA), *% of total*                                       1.0 (0.84-1.14)    1.2 (0.79-2.47)
  Total Plasma Desaturation Indices                                                                     
   16:1/16:0 palmitoleic/palmitic, *arbitrary unit*                                  0.11 (0.09-0.12)   0.11 (0.09-0.14)
   18:1n-9/18:0 oleic/stearic, *arbitrary unit*                                      0.67 (0.56-0.90)   1.27 (0.92-1.68)[\*\*](#TFN8){ref-type="table-fn"}
  VLDL Desaturation Indices[4](#TFN6){ref-type="table-fn"}                                              
   VLDL palmitoleic/palmitic index, *arbitrary unit*                                 0.03 (0.01-0.05)   0.06 (0.03-0.12)
   VLDL oleic/stearic index, *arbitrary unit*                                        0.18 (0.13-0.43)   0.76 (0.41-1.17)[\*](#TFN7){ref-type="table-fn"}

Data are all presented as the median with the 25-75% IQR because some variables exhibited non-normal distribution.

n=19 in Control group, n=18 in GDM group due to insufficient samples

see Methods for additional information related to interpretation

n=10 in each group due to insufficient samples to complete analysis in all subjects

p\<0.05,

p\<0.01, and

trend to difference, p\<0.1 compared with Controls.
